The rationale for the application of anti-EGFR monoclonal antibodies in KRAS exon 2 wt MCC cases depended on the appropriate concordance of mutational status between primary and metastatic tumours, as presented in previous literature [22, 23]. This evidence concerns the gene EGFR and metastatic neoplasm.